Outcomes for clinical trials of food allergy treatments.


Journal

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580

Informations de publication

Date de publication:
11 2020
Historique:
received: 10 12 2019
revised: 18 05 2020
accepted: 11 06 2020
pubmed: 23 6 2020
medline: 15 12 2020
entrez: 23 6 2020
Statut: ppublish

Résumé

Food allergy is a common condition that can have a significant impact on the quality of life of affected individuals and their caregivers. Recent years have witnessed an increased effort to identify new treatments for food allergy. Here, we review the need to identify core outcomes for measurement in clinical trials of food allergy treatments. We reviewed the literature regarding core outcome set development, the important role that these play in prioritizing patient-relevant outcomes, and the potential for core outcomes to accelerate the path to product marketing by allowing prompt and reliable evidence synthesis after trial publication. We reviewed recent clinical trials of food allergy treatments to understand which outcomes have previously been measured, and also reviewed available core outcome set initiatives for other allergic conditions to understand which other outcomes might be explored in future trials. Clinical trials of food allergy treatments have largely focused on outcomes that are relevant to investigators and commercial investors, especially the threshold of reactivity and immunologic changes. Future trials should consider addressing patient-important outcomes and should report the experiences of both adult and child participants and their caregivers. There is a pressing need for core outcome set development for food allergy treatment trials.

Identifiants

pubmed: 32569834
pii: S1081-1206(20)30418-X
doi: 10.1016/j.anai.2020.06.023
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

535-542

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Kathleen Sim (K)

Inflammation, Repair, and Development Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom.

Dragan Mijakoski (D)

Department of Allergy Center, Institute of Occupational Health, World Health Organization Collaborating Center, Global Allergy, and Asthma European Network Collaborating Center, Allergy Center, Skopje, Macedonia.

Sasho Stoleski (S)

Department of Allergy Center, Institute of Occupational Health, World Health Organization Collaborating Center, Global Allergy, and Asthma European Network Collaborating Center, Allergy Center, Skopje, Macedonia.

Pablo Rodriguez Del Rio (PR)

Allergy Department, Hospital Infantil Universitario Niño Jesus, Madrid, Spain; Health Research Institute Princesa, Madrid, Spain.

Patrick Sammut (P)

Department of Paediatrics, Respiratory Medicine, and Allergy, Mater Dei Hospital, Malta.

Thuy-My Le (TM)

Department of Dermatology/Allergology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.

Daniel Munblit (D)

Inflammation, Repair, and Development Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child Health, Sechenov First Moscow State Medical University, Moscow, the Russian Federation; Solov'ev Research and Clinical Center for Neuropsychiatry, Moscow, the Russian Federation.

Robert J Boyle (RJ)

Inflammation, Repair, and Development Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom; Centre of Evidence-based Dermatology, University of Nottingham, Nottingham, United Kingdom. Electronic address: r.boyle@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH